Cargo Therapeutics Inc. has announced a regulatory development following its merger with Concentra Biosciences, LLC. The company notified The Nasdaq Stock Market LLC of the merger's completion and requested the suspension of trading of its shares, effective before the market opens on August 19, 2025. Furthermore, Cargo Therapeutics has filed a Notification of Removal from Listing with the SEC to delist its shares from Nasdaq and deregister them under the Securities Exchange Act of 1934. The company also intends to terminate the registration of its shares and suspend reporting obligations. As a result of the merger, Cargo Therapeutics has become a wholly owned subsidiary of Concentra Biosciences.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cargo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-183141), on August 19, 2025, and is solely responsible for the information contained therein.